Comparative Pharmacology
Head-to-head clinical analysis: CIPROFLOXACIN EXTENDED RELEASE versus MOXAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPROFLOXACIN EXTENDED RELEASE versus MOXAM.
CIPROFLOXACIN EXTENDED RELEASE vs MOXAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication, transcription, repair, and recombination.
Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
500-1000 mg orally once daily for 7-14 days; extended-release tablet must be taken whole with a meal.
400 mg orally every 24 hours for 7-14 days.
None Documented
None Documented
Terminal elimination half-life approximately 11 hours, ranging from 10-14 hours in patients with normal renal function. Prolonged in renal impairment; requires dose adjustment.
Terminal elimination half-life: 6-8 hours; prolonged in renal impairment (up to 20 hours with CrCl <30 mL/min).
Primarily renal excretion (50-70% unchanged drug via glomerular filtration and tubular secretion); 15-25% metabolized; 20-35% fecal elimination via biliary secretion and intestinal epithelium.
Renal: ~70% unchanged; biliary/fecal: ~20% as unchanged drug and metabolites; minor metabolism via glucuronidation.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic